机译
18F-FDG和68Ga-DOTATATE PET / CT在von Hippel-Lindau综合征患者监测中的辅助作用
摘要:A 45-year-old woman with a history of von Hippel-Lindau (VHL) syndrome was evaluated during follow up with whole-body positron-emission tomography/computed tomography (PET/CT) scans post administration of Ga-DOTATATE (targets cell surface overexpression of somatostatin receptors) ( , ) and F-FDG (targets metabolic activity) ( , ) within two consecutive days. Ga-DOTATATE was taken up by a cerebral hemangioblastoma ( ) and revealed ( , ) 2 lesions in the head and the uncinate process of the pancreas; both were F-FDG negative, indicative of well-differentiated neuroendocrine tumors (NETs). Additionally, F-FDG revealed ( , ) a hypermetabolic tumor adjacent to the left adrenal gland, which was Ga-DOTATATE-negative. This tumor was surgically resected and was proven to be an extra-adrenal paraganglioma. VHL is a highly penetrant, autosomal, dominantly inherited disorder associated with a germline mutation of the VHL tumor suppressor gene on the short arm of chromosome 3. It is characterized by the development of several benign and malignant tumors, including hemangioblastomas, pancreatic NETs, and paragangliomas [ ]. Ga-DOTATATE is a radiolabeled somatostatin analog suitable for PET imaging, that has emerged as the imaging standard of reference for the diagnosis of well-differentiated NETs [ , ]. Furthermore, hemangioblastomas, which are highly vascular benign tumors, are known to be Ga-DOATATE-positive, as in the present case [ , ]. In addition, F-FDG is the most widely used PET-tracer for oncologic purposes, as it can contribute significantly to the detection and follow up of various VHL-related tumors. The presented data highlights the complementary role of Ga-DOTATATE and F-FDG for the accurate diagnosis of uncertain lesions in the context of the surveillance for patients with VHL.